Novan

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline includes SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Durham, NC.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novan develops products that tap the anti-bacterial properties of nitric oxide by encapsulating the compound in nano-particles that deliver therapeutic agents to desired body location. They use its proprietary nitric oxide-based science and technology platform to develop innovative, first-in-class therapies for unmet medical needs. The company is committed to using the power of the human body to create safe and effective treatments. They complement their internal scientific talent with strategic partners around the globe to enable Novan to harness the power of nitric oxide and develop technologies that will help address currently untreated and under-treated medical conditions. It was incorporated in 2008 and is based in Morrisville, North Carolina.

MORRISVILLE, N.C., March  03, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten public offering of 18,333,334 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase an aggregate of up to 18,333,334 shares of common stock, at a combined effective public offering price of $0.30 per share of common stock (or pre-funded warrant) and accompanying common warrant. The common warrants have an exercise price of $0.30 per share, are exercisable immediately and expire five years from the date of issuance. The Company also granted the underwriter a 30-day option to purchase up to an additional 2,750,000 shares of common stock and/or warrants to purchase 2,750,000 shares of common stock, which the underwriter partially exercised on March 2, 2020 to purchase 1,498,602 shares of common stock and common warrants to purchase up to 2,750,000 shares of common stock.

Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter’s Option to Purchase Additional Securities

MORRISVILLE, N.C., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering of 18,333,334 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase an aggregate of 18,333,334 shares of common stock, at a combined effective public offering price of $0.30 per share of common stock (or pre-funded warrant) and accompanying common warrant. The common warrants have an exercise price of $0.30 per share, are exercisable immediately and expire five years from the date of issuance. 

Novan Announces Pricing of $5.5 Million Public Offering

MORRISVILLE, N.C., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Novan Announces Proposed Public Offering

MORRISVILLE, N.C., Feb.  20, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received approximately $1.0 million funding from the National Institutes of Health (NIH) to cover the first year of a two-year Phase 2 federal grant. Novan is eligible to receive approximately $500,000 of additional funding for the second year, subject to availability of NIH funds and satisfactory progress of the project. This grant is additive to the approximately $223,000 Phase 1 NIH grant received in August 2019.

Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million

MORRISVILLE, N.C., Feb.  06, 2020  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2).  

Novan Provides SB206 Program and Business Update

Shares of Novan Inc. novn fell 72% in premarket trading on Friday after the biotechnology company said Thursday that its experimental treatment for molluscum contagiosum, a type of skin infection, had failed to meet the primary endpoints in two late-stage clinical trials.

Novan stock tumbles on failed trial

MORRISVILLE, N.C., Dec.  18, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, currently President and Chief Operating Officer (“COO”) of Novan, will succeed G. Kelly Martin as its Chief Executive Officer (“CEO”), effective February 2, 2020, and she will remain a member of the Novan Board of Directors.

Novan Announces Planned Chief Executive Officer Transition

Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for

MORRISVILLE, N.C., Oct.  18, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has submitted a request for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for new product candidate, SB207. The Company anticipates that the meeting will be held in December 2019.

Novan Further Expands its Proprietary Nitric Oxide Platform

MORRISVILLE, N.C., Oct.  08, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum, has been published in the Journal of the American Academy of Dermatology (“JAAD”). In this Phase 2 study, SB206 demonstrated clinical efficacy with a favorable safety profile.

Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

MORRISVILLE, N.C., Sept.  20, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received a grant from the U.S. Department of Defense’s (DoD) Congressionally Directed Medical Research Programs (CDMRP) of approximately $1.1 million as part of its Peer Reviewed Cancer Research Program.

Novan Awarded Approximately $1.1 Million Grant by Department of Defense

MORRISVILLE, N.C., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan’s Board of Directors granted stock options to purchase an aggregate of 25,000 shares of its common stock to a newly-hired employee with a grant date of September 6, 2019. The stock options were granted as an inducement material to the new employee entering into employment with Novan in accordance with Nasdaq Listing Rule 5635(c)(4).

Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the “Agreement”) of up to $25 million with Aspire Capital Fund, LLC (“Aspire Capital”), a Chicago-based institutional investor.

Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

MORRISVILLE, N.C., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced the appointment of Michelle Patterson as Vice President of Project Management.

News for Novan Stock (NOVN)